16 research outputs found

    La descentralización de la política pública de combate a la pobreza: Programa de desarrollo humano de oportunidades como experiencia de análisis 2002-2012

    Get PDF
    Una tarea esencial en el desenvolvimiento de las funciones del Estado es la generación de políticas públicas como agentes creadores de estabilidad social. Es en busca de dicha estabilidad que se diseñan programas de combate a la pobreza que a lo largo del tiempo pretendieron sanear los males sociales. En el contexto nacional se han instaurado cursos de acción como el Programa Nacional de Solidaridad (Pronasol), el Programa de Educación, Salud y Alimentación (Progresa) y en tiempos recientes el Programa de Desarrollo Humano Oportunidades, todos ellos con el fin de ser un anclaje seguro ante los vertiginosos cambios del mercado y males sociales. El presente trabajo toma como objeto de aplicación del conocimiento al Programa Oportunidades debido a su papel fundamental en el tratamiento a la pobreza y como referente de análisis en la construcción de una propuesta de descentralización. Para ello se efectúa la revisión de teorías como federalismo y descentralización, además de revisar los marcos de análisis referentes a las relaciones intergubernamentales (RIG´s), política pública y política social. Hablar de federalismo es hablar de la importancia que juegan los órdenes de gobierno en el sano desenvolvimiento de las funciones del Estado con el fin último de lograr el bien común

    Hitos Demográficos del Siglo XXI: Migración Internacional

    Get PDF
    La migración ha sido una constante en la historia mundial. Sin embargo, las migraciones que han tenido lugar desde principios del siglo XXI no tienen precedentes, ya que recientemente éstas han alcanzado su mayor volumen en la historia y presentan características que las diferencian de las observadas en periodos anteriores, lo que ha propiciado una nueva conceptualización del fenómeno, enmarcada en lo que algunos estudiosos llaman “la nueva era” de las migraciones internacionales (Arango, 2003, mencionado por Fernández, 2005). Este nuevo ciclo se caracteriza por una profusa re-configuración del mapa migratorio mundial, el cual parece dar cuenta hoy, de una auténtica mundialización migratoria, con una fuerte tendencia a la diversificación de rutas y conexiones origen-destino. El nuevo mapa es el correlato de un escenario de globalización económica, cultural e informacional, que estimula que segmentos amplios de la población respondan cada vez más rápidamente a informaciones y oportunidades que se originan más allá de las fronteras nacionales (CONAPO, 2009). De esta forma la nueva era de la globalización, se ha convertido en un asunto de especial trascendencia. Por un lado, la mejora y expansión de los sistemas de comunicación y transporte y la significativa reducción del tiempo y coste de desplazamiento, así como las disparidades económicas y la existencia de situaciones sociales y políticas extremas han propiciado el crecimiento de los movimientos transnacionales de personas y la intensificación de las presiones migratorias. En este sentido, España nunca ha sido ajena al fenómeno de las corrientes migratorias. Así por ejemplo, en los últimos años y durante la primera mitad del siglo XX y parte de la segunda, grandes contingentes de españoles emigraron hacia diferentes puntos de América Latina y Europa en busca de un empleo y mejor calidad de vida. Pero fue a finales del siglo pasado cuando España, impulsada por el acelerado ritmo de crecimiento económico adoptado en parte gracias a su integración económica en Europa, pasó de ser una economía emisora de emigrantes a una receptora de inmigrantes. Sin embargo, el fenómeno de la inmigración en España cobró verdadera importancia hasta principios del siglo XXI, cuando las fuertes oleadas masivas de personas provenientes de países en vías de desarrollo se dejaron sentir en su estructura poblacional y actividad laboral; de ésta manera, durante el primer quinquenio de este siglo si al 1 de enero del año 2000 los residentes extranjeros en España eran 0.9 millones (que representaban 2.3 por ciento de las personas empadronadas) al 1 de enero de 2005 ya eran 3.7 millones, es decir, 8.5 por ciento de la población residente en el país, habiéndose por tanto cuadriplicado el efectivo de extranjeros en tan sólo cinco años (González, 2006: 2-3; Gil, 2007: 1). Con base en lo anterior, el objetivo del presente trabajo consistió en analizar las características de los flujos de inmigración actuales en España procedentes de países latinoamericanos, enmarcados en la nueva re-configuración del mapa migratorio mundial

    Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

    Get PDF
    Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Odanacatib for the treatment of postmenopausal osteoporosis : Results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    No full text
    Background Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass. We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women with osteoporosis. Methods The Long-term Odanacatib Fracture Trial (LOFT) was a multicentre, randomised, double-blind, placebo-controlled, event-driven study at 388 outpatient clinics in 40 countries. Eligible participants were women aged at least 65 years who were postmenopausal for 5 years or more, with a femoral neck or total hip bone mineral density T-score between −2·5 and −4·0 if no previous radiographic vertebral fracture, or between −1·5 and −4·0 with a previous vertebral fracture. Women with a previous hip fracture, more than one vertebral fracture, or a T-score of less than −4·0 at the total hip or femoral neck were not eligible unless they were unable or unwilling to use approved osteoporosis treatment. Participants were randomly assigned (1:1) to either oral odanacatib (50 mg once per week) or matching placebo. Randomisation was done using an interactive voice recognition system after stratification for previous radiographic vertebral fracture, and treatment was masked to study participants, investigators and their staff, and sponsor personnel. If the study completed before 5 years of double-blind treatment, consenting participants could enrol in a double-blind extension study (LOFT Extension), continuing their original treatment assignment for up to 5 years from randomisation. Primary endpoints were incidence of vertebral fractures as assessed using radiographs collected at baseline, 6 and 12 months, yearly, and at final study visit in participants for whom evaluable radiograph images were available at baseline and at least one other timepoint, and hip and non-vertebral fractures adjudicated as being a result of osteoporosis as assessed by clinical history and radiograph. Safety was assessed in participants who received at least one dose of study drug. The adjudicated cardiovascular safety endpoints were a composite of cardiovascular death, myocardial infarction, or stroke, and new-onset atrial fibrillation or flutter. Individual cardiovascular endpoints and death were also assessed. LOFT and LOFT Extension are registered with ClinicalTrials.gov (number NCT00529373) and the European Clinical Trials Database (EudraCT number 2007-002693-66). Findings Between Sept 14, 2007, and Nov 17, 2009, we randomly assigned 16 071 evaluable patients to treatment: 8043 to odanacatib and 8028 to placebo. After a median follow-up of 36·5 months (IQR 34·43–40·15) 4297 women assigned to odanacatib and 3960 assigned to placebo enrolled in LOFT Extension (total median follow-up 47·6 months, IQR 35·45–60·06). In LOFT, cumulative incidence of primary outcomes for odanacatib versus placebo were: radiographic vertebral fractures 3·7% (251/6770) versus 7·8% (542/6910), hazard ratio (HR) 0·46, 95% CI 0·40–0·53; hip fractures 0·8% (65/8043) versus 1·6% (125/8028), 0·53, 0·39–0·71; non-vertebral fractures 5·1% (412/8043) versus 6·7% (541/8028), 0·77, 0·68–0·87; all p<0·0001. Combined results from LOFT plus LOFT Extension for cumulative incidence of primary outcomes for odanacatib versus placebo were: radiographic vertebral fractures 4·9% (341/6909) versus 9·6% (675/7011), HR 0·48, 95% CI 0·42–0·55; hip fractures 1·1% (86/8043) versus 2·0% (162/8028), 0·52, 0·40–0·67; non-vertebral fractures 6·4% (512/8043) versus 8·4% (675/8028), 0·74, 0·66–0·83; all p<0·0001. In LOFT, the composite cardiovascular endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 273 (3·4%) of 8043 patients in the odanacatib group versus 245 (3·1%) of 8028 in the placebo group (HR 1·12, 95% CI 0·95–1·34; p=0·18). New-onset atrial fibrillation or flutter occurred in 112 (1·4%) of 8043 patients in the odanacatib group versus 96 (1·2%) of 8028 in the placebo group (HR 1·18, 0·90–1·55; p=0·24). Odanacatib was associated with an increased risk of stroke (1·7% [136/8043] vs 1·3% [104/8028], HR 1·32, 1·02–1·70; p=0·034), but not myocardial infarction (0·7% [60/8043] vs 0·9% [74/8028], HR 0·82, 0·58–1·15; p=0·26). The HR for all-cause mortality was 1·13 (5·0% [401/8043] vs 4·4% [356/8028], 0·98–1·30; p=0·10). When data from LOFT Extension were included, the composite of cardiovascular death, myocardial infarction, or stroke occurred in significantly more patients in the odanacatib group than in the placebo group (401 [5·0%] of 8043 vs 343 [4·3%] of 8028, HR 1·17, 1·02–1·36; p=0·029, as did stroke (2·3% [187/8043] vs 1·7% [137/8028], HR 1·37, 1·10–1·71; p=0·0051). Interpretation Odanacatib reduced the risk of fracture, but was associated with an increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis. Based on the overall balance between benefit and risk, the study's sponsor decided that they would no longer pursue development of odanacatib for treatment of osteoporosis

    Make EU trade with Brazil sustainable

    Get PDF
    Brazil, home to one of the planet's last great forests, is currently in trade negotiations with its second largest trading partner, the European Union (EU). We urge the EU to seize this critical opportunity to ensure that Brazil protects human rights and the environment
    corecore